$BNTX (+0,42 %) The companies will work together to develop and eventually sell BNT327, one of BioNTech's developmental antibodies that is in trials to treat a number of types of tumors. More than 20 trials are ongoing or planned to study the drug's effectiveness in treating certain lung, breast, and other types of cancer.
Princeton, N.J.-based Bristol Myers Squibb "will pay BioNTech $1.5 billion in an upfront payment and $2 billion total in non-contingent anniversary payments through 2028." BioNTech is also eligible to receive up to $7.6 billion in future payments based on certain developmental and regulatory milestones, while the companies will share manufacturing costs and profits or losses.
Meine mit ein Medikament das Potenzial der ganzen Market cap raus zuholen ist schon crazy. Mal schauen wie die ganze Pipeline aussieht